Blokhin Elena, Pulitzer Melissa, Busam Klaus J
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
J Cutan Pathol. 2013 Sep;40(9):796-800. doi: 10.1111/cup.12186. Epub 2013 Jun 29.
Desmoplastic melanoma can be difficult to distinguish from desmoplastic melanocytic nevi both clinically and histopathologically. Several attempts have been made to explore the use of ancillary studies to facilitate this distinction. Prior work has suggested that immunohistochemical expression of p16 could help distinguish sclerosing Spitz nevi from desmoplastic melanomas. We re-evaluated the expression of p16 in 22 desmoplastic melanomas (13 mixed and 9 pure desmoplastic tumors) and five desmoplastic melanocytic nevi (three desmoplastic Spitz nevi and two congenital melanocytic nevi with prominent dermal sclerosis). All desmoplastic melanocytic nevi were strongly immunoreactive for p16. Of the 22 desmoplastic melanomas, 6 tumors failed to label for p16, 10 were focally positive, but 6 tumors were diffusely immunoreactive. The latter finding is relevant, as it points to limitations in the diagnostic value of immunohistochemical staining for p16 for the diagnosis of desmoplastic melanocytic proliferations. Diffuse staining for p16 is not restricted to desmoplastic Spitz nevi but can also occur in a subset of desmoplastic melanomas, and this warrants caution in the use of this marker for diagnostic purposes.
促纤维增生性黑色素瘤在临床和组织病理学上都可能难以与促纤维增生性黑素细胞痣相区分。人们已经进行了几次尝试,探索使用辅助研究来促进这种区分。先前的研究表明,p16的免疫组化表达有助于区分硬化性斯皮茨痣和促纤维增生性黑色素瘤。我们重新评估了22例促纤维增生性黑色素瘤(13例混合型和9例纯促纤维增生性肿瘤)和5例促纤维增生性黑素细胞痣(3例促纤维增生性斯皮茨痣和2例具有显著真皮硬化的先天性黑素细胞痣)中p16的表达。所有促纤维增生性黑素细胞痣对p16均呈强免疫反应性。在22例促纤维增生性黑色素瘤中,6例肿瘤p16未标记,10例局灶阳性,但6例肿瘤弥漫性免疫反应性。后一发现具有相关性,因为它指出了p16免疫组化染色对促纤维增生性黑素细胞增殖诊断价值的局限性。p16弥漫性染色并不局限于促纤维增生性斯皮茨痣,也可出现在一部分促纤维增生性黑色素瘤中,这就需要在将该标志物用于诊断目的时谨慎行事。